237 related articles for article (PubMed ID: 16465612)
1. Rheumatoid arthritis: inflammation and bone loss.
Schett G
Wien Med Wochenschr; 2006 Jan; 156(1-2):34-41. PubMed ID: 16465612
[TBL] [Abstract][Full Text] [Related]
2. New insights in the mechanism of bone loss in arthritis.
Schett G; Smolen JS
Curr Pharm Des; 2005; 11(23):3039-49. PubMed ID: 16178762
[TBL] [Abstract][Full Text] [Related]
3. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
4. [Osteoclastic bone resorption in joint destruction of rheumatoid arthritis].
Kawaguchi H
Ryumachi; 2000 Feb; 40(1):32-8. PubMed ID: 10783664
[No Abstract] [Full Text] [Related]
5. Total Saponin from Anemone flaccida Fr. Schmidt Prevents Bone Destruction in Experimental Rheumatoid Arthritis via Inhibiting Osteoclastogenesis.
Liu C; Yang Y; Sun D; Wang C; Wang H; Jia S; Liu L; Lin N
Rejuvenation Res; 2015 Dec; 18(6):528-42. PubMed ID: 26418168
[TBL] [Abstract][Full Text] [Related]
6. [Role of osteoclasts in bone destruction in rheumatoid arthritis].
Suzuki Y
Nihon Rinsho Meneki Gakkai Kaishi; 2001 Jun; 24(3):87-97. PubMed ID: 16578961
[No Abstract] [Full Text] [Related]
7. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.
Koenders MI; Lubberts E; Oppers-Walgreen B; van den Bersselaar L; Helsen MM; Di Padova FE; Boots AM; Gram H; Joosten LA; van den Berg WB
Am J Pathol; 2005 Jul; 167(1):141-9. PubMed ID: 15972960
[TBL] [Abstract][Full Text] [Related]
8. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
[TBL] [Abstract][Full Text] [Related]
9. Osteoclasts, pro-inflammatory cytokines, RANK-L and bone remodeling in rheumatoid arthritis.
Kaplan C; Finnegan A
Front Biosci; 2003 May; 8():d1018-29. PubMed ID: 12700082
[TBL] [Abstract][Full Text] [Related]
10. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
[TBL] [Abstract][Full Text] [Related]
11. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.
Ohtsuji M; Lin Q; Nishikawa K; Ohtsuji N; Okazaki H; Tsurui H; Amano H; Shirai T; Nishimoto N; Nishimura H; Hirose S
Mod Rheumatol; 2015 Mar; 25(2):270-7. PubMed ID: 25159156
[TBL] [Abstract][Full Text] [Related]
12. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
Anandarajah AP; Schwarz EM
J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
[TBL] [Abstract][Full Text] [Related]
13. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
Romas E
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1065-79. PubMed ID: 16301197
[TBL] [Abstract][Full Text] [Related]
14. A microbial polysaccharide reduces the severity of rheumatoid arthritis by influencing Th17 differentiation and proinflammatory cytokines production.
Monari C; Bevilacqua S; Piccioni M; Pericolini E; Perito S; Calvitti M; Bistoni F; Kozel TR; Vecchiarelli A
J Immunol; 2009 Jul; 183(1):191-200. PubMed ID: 19542430
[TBL] [Abstract][Full Text] [Related]
15. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis.
Lubberts E; Oppers-Walgreen B; Pettit AR; Van Den Bersselaar L; Joosten LA; Goldring SR; Gravallese EM; Van Den Berg WB
Arthritis Rheum; 2002 Nov; 46(11):3055-64. PubMed ID: 12428250
[TBL] [Abstract][Full Text] [Related]
16. Morphological characterization of receptor activator of NFkappaB ligand (RANKL) and IL-1beta expression in rodent collagen-induced arthritis.
Weiss RJ; Erlandsson Harris H; Wick MC; Wretenberg P; Stark A; Palmblad K
Scand J Immunol; 2005 Jul; 62(1):55-62. PubMed ID: 16092922
[TBL] [Abstract][Full Text] [Related]
17. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
Mori T; Miyamoto T; Yoshida H; Asakawa M; Kawasumi M; Kobayashi T; Morioka H; Chiba K; Toyama Y; Yoshimura A
Int Immunol; 2011 Nov; 23(11):701-12. PubMed ID: 21937456
[TBL] [Abstract][Full Text] [Related]
18. Rheumatic diseases: the effects of inflammation on bone.
Walsh NC; Crotti TN; Goldring SR; Gravallese EM
Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
[TBL] [Abstract][Full Text] [Related]
19. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models.
Lubberts E; Koenders MI; van den Berg WB
Arthritis Res Ther; 2005; 7(1):29-37. PubMed ID: 15642151
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.
Binder NB; Puchner A; Niederreiter B; Hayer S; Leiss H; Blüml S; Kreindl R; Smolen JS; Redlich K
Arthritis Rheum; 2013 Mar; 65(3):608-17. PubMed ID: 23280418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
